Skip to content
ClinCalc Pro
Menu
Alpha-2 Agonist — Analgesic Adjunct / Sedation

Clonidine

Brand names: Catapres, Duraclon (epidural)

Clonidine is a centrally acting alpha-2 adrenoceptor agonist used perioperatively as an anaesthetic adjunct and sedative, to attenuate sympathetic responses, reduce opioid requirements and treat postoperative shivering.

Dosing — not shown for this use

The product information we hold does not support a dose for this page's specific use, route or population, so none is shown. Follow your local or national guideline, and confirm against the product SmPC.

The licensed dosing — for the medicine's licensed uses, which may differ from this page's — is on Clonidine hydrochloride.

Clinical monograph

How it works

It stimulates central alpha-2 adrenoceptors in the brainstem, reducing sympathetic outflow and noradrenaline release, which lowers heart rate and blood pressure and produces sedation and analgesia.

Prescribing in practice

  • Abrupt withdrawal after sustained use can precipitate rebound hypertension and tachycardia, so taper rather than stop suddenly and avoid in patients with significant bradyarrhythmia.
  • Causes dose-dependent hypotension, bradycardia and sedation that can be additive with anaesthetic agents and other CNS depressants.
  • Use cautiously in cerebrovascular or ischaemic heart disease and in those with impaired renal function, who may need a reduced dose.

Monitoring

Monitor heart rate, blood pressure and conscious level closely during and after perioperative administration.

Counselling the patient

  • Expect drowsiness, a dry mouth and possible light-headedness when standing.
  • Do not stop the medicine abruptly if you have been taking it regularly.

Evidence & guidelines

Perioperative use is supported by anaesthetic guidance and trials showing reduced opioid requirement and attenuated haemodynamic stress responses.

Reference: Catapres SPC; PROSPECT Clonidine Review; Eisenach et al. (perineural clonidine); AAGBI; Drug verified in RxNorm (NLM); confirm dosing against the manufacturer SPC (eMC). Verify against your local formulary and current prescribing references before prescribing. Monograph status: clinician-reviewed (2026-07-04).

Related

Curated clinical cross-links plus same-class fallbacks.